Search Results - "Arthur T. Skarin"

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer by JACKMAN, David M, YEAP, Beow Y, FREIDLIN, Boris, OSTLER, Patricia A, LUCCA, Joan, LYNCH, Thomas J, JOHNSON, Bruce E, JDNNE, Pasi A, LINDEMAN, Neal I, FIDIAS, Panos, RABIN, Michael S, TEMEL, Jennifer, SKARIN, Arthur T, MEYERSON, Matthew, HOLMES, Alison J, BORRAS, Ana M

“…This is a phase II, multicenter, open-label study of chemotherapy-naïve patients with non-small-cell lung cancer (NSCLC) and age > or = 70 years who were…”
Get full text

Radiofrequency Ablation of Thoracic Lesions: Part 2, Initial Clinical Experience--Technical and Multidisciplinary Considerations in 30 Patients by vanSonnenberg, Eric, Shankar, Sridhar, Morrison, Paul R, Nair, Rashmi T, Silverman, Stuart G, Jaklitsch, Michael T, Liu, Franklin, Cheung, Lawrence, Tuncali, Kemal, Skarin, Arthur T, Sugarbaker, David J

“…The purpose of our study was to report our initial experience with patients who underwent percutaneous imaging-guided radiofrequency ablation of thoracic…”
Get full text

Clinical Mimics of Lymphoma by Brown, Jennifer R., Skarin, Arthur T.

“…Learning Objectives After completing this course, the reader will be able to: Determine when lymphadenopathy is of concern and merits biopsy. Identify the…”
Get full text

Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer by John R. Goffin, Ian C. Anderson, Jeffrey G. Supko, Joseph Paul Eder, Jr, Geoffrey I. Shapiro, Thomas J. Lynch, Margaret Shipp, Bruce E. Johnson, Arthur T. Skarin

“…Purpose: Marimastat is an orally bioavailable inhibitor of matrix metalloproteinases. A phase I study was initiated to determine whether conventional doses of…”
Get full text

The epidemiology of herpes zoster and its complications in Medicare cancer patients by Yenikomshian, Mihran A, Guignard, Adrienne P, Haguinet, François, LaCasce, Ann S, Skarin, Arthur T, Trahey, Alex, Karner, Paul, Duh, Mei Sheng

“…Literature on the epidemiology of herpes zoster (HZ) in cancer patients is sparse and does not include the elderly. The objectives of this study were to…”
Get full text

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study by Jänne, Pasi A., Gurubhagavatula, Sarada, Yeap, Beow Y., Lucca, Joan, Ostler, Patricia, Skarin, Arthur T., Fidias, Panos, Lynch, Thomas J., Johnson, Bruce E.

“…Purpose: To investigate the anti-tumor activity and toxicity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa™; AstraZeneca…”
Get full text

Non-Hodgkin's lymphomas: current classification and management by Skarin, A. T, Dorfman, D. M

“…Considerable progress has been made in the classification of non-Hodgkin's lymphomas during the past 15 years, and the use of specific monoclonal antibodies…”
Get full text

Chemotherapy and surgery in stage IIIa non-small cell lung cancer by Skarin, Arthur T

Get more information

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis by Sheng Duh, Mei, Reynolds Weiner, Jennifer, Lefebvre, Patrick, Neary, Maureen, Skarin, Arthur T.

“…ABSTRACT Objectives: With new oral chemotherapy drugs emerging, it is useful to understand the costs associated with traditional intravenous (IV) therapy. This…”
Get full text

Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer by BHARTI, Ajit, MA, Patrick C, MAULIK, Gautam, SINGH, Rajeev, KHAN, Eshan, SKARIN, Arthur T, SALGIA, Ravi

“…Small cell lung cancer (SCLC) frequently presents as metastatic disease. It would be useful to detect serum tumor biomarkers at an earlier stage in order to…”
Get full text

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer by Fidias, Panos, Pennell, Nathan A, Boral, Anthony L, Shapiro, Geoffrey I, Skarin, Arthur T, Eder, Jr, Joseph P, Kwoh, T Jesse, Geary, Richard S, Johnson, Bruce E, Lynch, Thomas J, Supko, Jeffrey G

“…A phase I trial was performed to evaluate the administration of carboplatin/paclitaxel in combination with ISIS-5132, a phosphorothioate antisense…”
Get more information

Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors by Pisick, Evan, Skarin, Arthur T, Salgia, Ravi

“…Small blue cell tumors are a group of tumors that share a common histologic characteristic with H&E staining. This makes differentiation from one another…”
Get more information

Lung cancer in patients under age 40 by Skarin, Arthur T., Herbst, Roy S., Leong, Traci L., Bailey, Allison, Sugarbaker, David

“…A retrospective review of patients <40 years ( n=91) seen at the Dana-Farber Cancer Institute and Brigham and Women's Hospital from January 1, 1983–January 1,…”
Get full text

Circulating tumor cells and serum tumor biomarkers in small cell lung cancer by Ma, Patrick C, Blaszkowsky, Lawrence, Bharti, Ajit, Ladanyi, Andras, Kraeft, Stine-Kathrein, Bruno, Adam, Skarin, Arthur T, Chen, Lan Bo, Salgia, Ravi

“…Lung cancer accounts for approximately 30% of all cancer mortalities in the United States. Small cell lung cancer (SCLC), which is an aggressive malignancy…”
Get more information

Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome by ELIAS, A, IBRAHIM, J, SKARIN, A. T, WHEELER, C, MCCAULEY, M, AYASH, L, RICHARDSON, P, SCHNIPPER, L, ANTMAN, K. H, FREI, E. III

“…To determine progression-free survival (PFS) and overall long-term survival for limited-stage small-cell lung cancer (SCLC) patients aged 60 years or younger…”
Get full text

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: A Phase I study by WIRTH, Lori J, LUCCA, Joan, LUKANICH, Jeanne M, CHOI, Noah C, BERMAN, Stuart M, SKARIN, Arthur T, OSTLER, Patricia, FIDIAS, Panos, LYNCH, Cathy, JÄNNE, Pasi A, HERBST, Roy S, JOHNSON, Bruce E, SUGARBAKER, David J, MATHISEN, Douglas J

“…To determine the maximum-tolerated dose of docetaxel (DOC) in combination with carboplatin (CAR) and thoracic radiotherapy (RT), in the setting of trimodality…”
Get full text

Mucoepidermoid carcinoma of the lung with t(11:19)(q21:p13): a link to new biology by Roberts, Jr, Thomas G, Barry, Marc, Skarin, Arthur T

Get more information

Concurrent Docetaxel and Thoracic Radiation in non—small-Cell Lung Cancer by Jänne, Pasi A., Skarin, Arthur T.

“…Locally advanced (stages IIIA and IIIB) non—small-cell lung cancer (NSCLC) represents approximately 25% of new cases of NSCLC diagnosed annually. The treatment…”
Get full text

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial by HERBST, Roy S, LYNCH, Cathleen, SALGIA, Ravi, SKARIN, Arthur T, VASCONCELLES, Michael, TEICHER, Beverly A, STRAUSS, Gary, ELIAS, Anthony, ANDERSON, Ian, ZACAROLA, Patrick, DANG, Nam H, LEONG, Traci

“…This study was designed to assess the efficacy of gemcitabine plus vinorelbine using the mouse Lewis lung carcinoma model and to translate this regimen to a…”
Get full text

Radiotherapy Versus Chemotherapy plus Radiotherapy in Surgically Treated IIIA N2 non—small-Cell Lung Cancer by Elias, Anthony D., Kumar, Parvesh, Herndon, James, Skarin, Arthur T., Sugarbaker, David J., Green, Mark R.

“…Preoperative chemotherapy in patients with stage III non—small-cell lung cancer (NSCLC) remains controversial. Phase II trials utilizing preoperative…”
Get full text